Analysts expect Matinas BioPharma Holdings, Inc. to report revenue of 315,906.00 for Q2 23, against a range of 305,902.52 to 325,909.48. The most recent reported quarter, Q3 24, came in at 0.00.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.10 M | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | |||||||||||||||
| High Estimate | 314,015.58 | 325,909.48 | 333,218.87 | 326,756.92 | 0.00 | 0.00 | 0.00 | 0.00 | -12,958.64 | -88,929.09 | 31,709.34 | 91,980.13 | 22.44 M | |||||||||||||||
| Low Estimate | 257,325.42 | 305,902.52 | 302,145.13 | 296,631.08 | 0.00 | 0.00 | 0.00 | 0.00 | -15,097.08 | -101,354.81 | 27,283.08 | 80,112.29 | 18.51 M | |||||||||||||||
| Consensus Estimate | 285,670.50 | 315,906.00 | 317,682.00 | 311,694.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14,027.86 | -95,141.95 | 29,496.21 | 86,046.21 | 20.47 M |
Analysts expect Matinas BioPharma Holdings, Inc. to report earnings per share of -11.34 for Q4 24, against a range of -12.09 to -10.59. The most recent reported quarter, Q2 26, came in at -0.21, a 99.0% beat against the -21.10 consensus.
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -22.50 | -22.50 | -22.50 | -15.00 | -22.50 | -15.00 | -12.75 | - | -0.33 | -1.03 | -0.40 | -0.35 | -0.30 | -0.21 | - | - | - | - | - | - | - | |||||||
| High Estimate | -22.30 | -20.63 | -21.59 | -21.96 | -22.47 | -17.28 | -14.00 | -10.59 | -13.34 | -6.20 | -2.03 | 0.11 | -22.20 | -19.48 | -15.21 | -12.96 | -15.30 | -10.68 | -5.68 | -3.03 | 28.08 | |||||||
| Low Estimate | -23.92 | -23.53 | -23.57 | -25.02 | -24.81 | -18.66 | -15.60 | -12.09 | -14.56 | -6.68 | -2.29 | 0.09 | -24.22 | -22.72 | -16.33 | -14.24 | -17.52 | -11.66 | -6.78 | -3.41 | 23.20 | |||||||
| Consensus Estimate | -23.11 | -22.08 | -22.58 | -23.49 | -23.64 | -17.97 | -14.80 | -11.34 | -13.95 | -6.44 | -2.16 | 0.10 | -23.21 | -21.10 | -15.77 | -13.60 | -16.41 | -11.17 | -6.23 | -3.22 | 25.64 |
Pull Wall Street consensus for Matinas BioPharma Holdings, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=MTNB&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "MTNB", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=MTNB&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();